Intellia Raises $70m To Sharpen CRISPR Scissors
This article was originally published in Scrip
Intellia Therapeutics raised a $70m Series B venture capital round that the Cambridge, Massachusetts-based company will use to sharpen its approach to CRISPR/Cas9, a pair of molecular scissors used to edit genes involved in hard-to-treat diseases.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.